California-based institutionsTranscriptic，机器人云实验室平台，以及3Scan, a digital 3D tissue model specialist, have announced a merger to form the companyStrateos.
新成立的实体结合了前两家公司的工程能力，以帮助在封闭的Loop机器人实验室中自动化化学，生物学和3D图像分析，以加速药物发现计划。在新公司的成立之外，Stratigos董事会还宣布了其新任首席执行官兼Mark-Fischer Colbrie总裁，他还将在董事会担任。
“Accelerating discovery and achieving breakthroughs more efficiently has been an on-going goal of mine for decades,” commented Colbrie.
“I am pleased to join this group of innovators and to help hone cutting edge technologies as we become the preferred partner to biopharma in their discovery and development efforts.”
Combining robotics and 3D imaging to advance drug discovery
来自转录的机器人云实验室旨在通过为其研究提供一个自动化和可扩展的平台，以“加速上市，降低成本并提高生命科学公司的可重复性”。由于这种转录旨在通过各种不同行业的专业知识来提高药物发现和研究。
3Scan, on the other hand, focuses on creating detailed 3D representations of tissue models by using automation and machine learning to extract spatial data from tissue samples. Its technology also enables the quantitative image analysis of conditions like cancer, Parkinson’s, Alzheimer’s, and Huntington’s disease.
Significantly, both the companies have a history of utilizing robotics and artificial intelligence to aid the pharmaceutical drug discovery process. Their portfolios will be combined under Strateos to further advance the drug discovery process for pharmaceutical companies by providing an expanded selection of technologies, including 3D imaging. As both companies operate in California, their close proximity aids the integration of their businesses.
“The future of scientific discovery is now happening at the edge where disciplines meet, where advanced biology and high-tech engineering combine, where wet labs, chemistry, 3D imaging and robotic automation technologies operate together to unleash more control andcreativity from scientists than ever before possible,” commented Strateos Board member and Lux Capital Managing Director Josh Wolfe. “We are thrilled to help build a globally impactful and historic company.”
3D imaging enables medical breakthroughs
In what could be seen as a complement to 3D bioprinting,3D imaging technologyis continuously being used in medicine to advance the analysis of tissue models,microorganisms,embryos, andorgans.
In 2018, researchers at theUniversity of St Andrewsin Scotland discovered two new techniques for creating3D images of internal, biological tissues. The new 3D scanning methods were able to provide a complete 3D image without rotating or taking multiple images of a specimen. TheUniversity of Leuven（Ku Leuven）和生命科学研究所氛围have also recently developed a multi-color method of imaging biological matter.
Following the merger, Strateos has also revealed additional investments of $16.5M from venture capital firms DCVC (Data Collective) and Lux Capital, with support from Dolby Family Ventures as well. The funding will help to support the company’s expansion and overall mission.
“As a longtime lead investor in both companies, DCVC anticipates the combined entity will be exponentially more impactful,” explained Armen Vidian, Strateos Board member and DCVC Operating Partner. “Each of these companies has enabled multinational pharmaceutical companies to dramatically improve the efficiency of their drug discovery programs.”
“但总的来说,Strateos可以变换speed, scale, cost, and precision of scientists’ ability to discover new life-saving medicines across multiple steps in the discovery process.”
您现在可以投票参加第三届年度3D Printing Industry Awards. Help decide this year’s winners现在.
订阅3D Printing Industry newsletterfor the latest news in additive manufacturing. You can also keep connected by following us onTwitterand liking us onFacebook.
Looking for a career in additive manufacturing? Visit3D Printing Jobsfor a selection of roles in the industry.
Featured image shows Murine Lung Mesh Reconstruction. Image via 3Scan.
